Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration
October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.
VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.
For more information about VARUBI, please access:
https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html
Top resources
In Shawn’s corner: Stepping into the ring to end CRC
Shawn has lived with Crohn’s disease since age 10, a condition that raises his risk of colorectal cancer. He’s stepping into the ring with Haymakers for Hope to help end this disease, and he wants you in his corner.
FDA approves immunotherapy for MSI-H/dMMR stage II & III rectal cancer
The U.S. Food and Drug Administration approved dostarlimab (brand name Jemperli) as the first and only immunotherapy for adults with stage II or III rectal cancer that has a biomarker called MSI-H or dMMR.
Jenny Trefzger: "My missed expiration date"
Jenny Trefzger was 23 when gender-affirming care found her colon cancer. Nine years later, she wants readers to know that you don't have to be extraordinary to beat cancer.